Close Menu

NEW YORK (GenomeWeb) – As it pushed forward with a Phase I/IIa trial of its expressed RNAi-based treatment for hepatitis C, Benitec Biopharma said that it has streamlined the rest of its pipeline to focus on three other programs — hepatitis B, non-small cell lung cancer (NSCLC), and age-related macular degeneration (AMD).

Meanwhile, the company has struck licensing deals for DNA production and delivery technologies that it intends to develop for use with these upcoming clinical candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.

May
21
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.

Jun
04
Sponsored by
NanoCellect

This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance. 

Jun
06
Sponsored by
NRGene & Illumina

This webinar will discuss the impact of affordable de novo genome assemblies on crop research.